Switch theme
Sign up to access all valuation multiples
Aier Eye Hospital Group Co Ltd provides international ophthalmic technology and management services in China. The company offers services in myopia surgery, cataract, pediatric, eye plastic surgery, myopia prevention and control to patients. The group also enables high-standard medical care.
2003
2.7K+
LTM Revenue $3.1B
LTM EBITDA $905M
$16.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Aier EYE Hospital Group has a last 12-month revenue (LTM) of $3.1B and a last 12-month EBITDA of $905M.
In the most recent fiscal year, Aier EYE Hospital Group achieved revenue of $2.9B and an EBITDA of $894M.
Aier EYE Hospital Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Aier EYE Hospital Group valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.1B | XXX | $2.9B | XXX | XXX | XXX |
| Gross Profit | $1.5B | XXX | $1.4B | XXX | XXX | XXX |
| Gross Margin | 49% | XXX | 48% | XXX | XXX | XXX |
| EBITDA | $905M | XXX | $894M | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 31% | XXX | XXX | XXX |
| EBIT | $706M | XXX | $664M | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | 23% | XXX | XXX | XXX |
| Net Profit | $528M | XXX | $494M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Aier EYE Hospital Group's stock price is CNY 12 (or $2).
Aier EYE Hospital Group has current market cap of CNY 116B (or $16.1B), and EV of CNY 115B (or $16.0B).
See Aier EYE Hospital Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $16.0B | $16.1B | XXX | XXX | XXX | XXX | $0.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Aier EYE Hospital Group has market cap of $16.1B and EV of $16.0B.
Aier EYE Hospital Group's trades at 5.5x EV/Revenue multiple, and 17.9x EV/EBITDA.
Equity research analysts estimate Aier EYE Hospital Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Aier EYE Hospital Group has a P/E ratio of 30.4x.
See valuation multiples for Aier EYE Hospital Group and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $16.1B | XXX | $16.1B | XXX | XXX | XXX |
| EV (current) | $16.0B | XXX | $16.0B | XXX | XXX | XXX |
| EV/Revenue | 5.2x | XXX | 5.5x | XXX | XXX | XXX |
| EV/EBITDA | 17.7x | XXX | 17.9x | XXX | XXX | XXX |
| EV/EBIT | 22.7x | XXX | 24.1x | XXX | XXX | XXX |
| EV/Gross Profit | 10.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 30.4x | XXX | 32.5x | XXX | XXX | XXX |
| EV/FCF | 24.6x | XXX | 37.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAier EYE Hospital Group's last 12 month revenue growth is 13%
Aier EYE Hospital Group's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $0.3M for the same period.
Aier EYE Hospital Group's rule of 40 is 43% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Aier EYE Hospital Group's rule of X is 62% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Aier EYE Hospital Group and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 31% | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | 8% | XXX | XXX | XXX |
| Rule of 40 | 43% | XXX | 44% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 62% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 25% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Burjeel Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| PureHealth | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ramsay Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Athens Medical Centre | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aier EYE Hospital Group acquired XXX companies to date.
Last acquisition by Aier EYE Hospital Group was XXXXXXXX, XXXXX XXXXX XXXXXX . Aier EYE Hospital Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Aier EYE Hospital Group founded? | Aier EYE Hospital Group was founded in 2003. |
| Where is Aier EYE Hospital Group headquartered? | Aier EYE Hospital Group is headquartered in China. |
| How many employees does Aier EYE Hospital Group have? | As of today, Aier EYE Hospital Group has 2.7K+ employees. |
| Is Aier EYE Hospital Group publicy listed? | Yes, Aier EYE Hospital Group is a public company listed on SHE. |
| What is the stock symbol of Aier EYE Hospital Group? | Aier EYE Hospital Group trades under 300015 ticker. |
| When did Aier EYE Hospital Group go public? | Aier EYE Hospital Group went public in 2009. |
| Who are competitors of Aier EYE Hospital Group? | Similar companies to Aier EYE Hospital Group include e.g. Burjeel Holdings, PureHealth, Integral Diagnostics, Ramsay Health. |
| What is the current market cap of Aier EYE Hospital Group? | Aier EYE Hospital Group's current market cap is $16.1B |
| What is the current revenue of Aier EYE Hospital Group? | Aier EYE Hospital Group's last 12 months revenue is $3.1B. |
| What is the current revenue growth of Aier EYE Hospital Group? | Aier EYE Hospital Group revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Aier EYE Hospital Group? | Current revenue multiple of Aier EYE Hospital Group is 5.2x. |
| Is Aier EYE Hospital Group profitable? | Yes, Aier EYE Hospital Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Aier EYE Hospital Group? | Aier EYE Hospital Group's last 12 months EBITDA is $905M. |
| What is Aier EYE Hospital Group's EBITDA margin? | Aier EYE Hospital Group's last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of Aier EYE Hospital Group? | Current EBITDA multiple of Aier EYE Hospital Group is 17.7x. |
| What is the current FCF of Aier EYE Hospital Group? | Aier EYE Hospital Group's last 12 months FCF is $650M. |
| What is Aier EYE Hospital Group's FCF margin? | Aier EYE Hospital Group's last 12 months FCF margin is 21%. |
| What is the current EV/FCF multiple of Aier EYE Hospital Group? | Current FCF multiple of Aier EYE Hospital Group is 24.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
